Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy
- 6 November 2013
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 50 (1) , 47-51
Abstract
Introduction: We determined health plan paid costs and healthcare resource usage of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database. We examined demographics, prevalence of comorbidities, prescribed drugs, place of service, and mean annual health plan paid costs per patient. Results: From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria. The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%). The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs. Conclusions: Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy usage. Studies are needed to determine optimal long‐term treatment strategies for CIDP, particularly related to IVIg. Muscle Nerve 50: 47–51, 2014Keywords
Funding Information
- American Academy of Neurology Foundation and the Myasthenia Gravis Foundation of America
This publication has 19 references indexed in Scilit:
- Medical costs and health‐care resource use in patients with inflammatory myopathies in an insured populationMuscle & Nerve, 2012
- Cost analysis of myasthenia gravis from a large U.S. insurance databaseMuscle & Nerve, 2011
- Estimated cost of treating myasthenia gravis in an insured U.S. populationMuscle & Nerve, 2011
- Advances in the diagnosis, pathogenesis and treatment of CIDPNature Reviews Neurology, 2011
- Treatment of Neuropathic Pain: An Overview of Recent GuidelinesThe American Journal of Medicine, 2009
- Incidence and prevalence of CIDP and the association of diabetes mellitusNeurology, 2009
- Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpuraClinical Therapeutics, 2009
- EFNS guidelines on pharmacological treatment of neuropathic painEuropean Journal of Neurology, 2006
- Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathyEuropean Journal of Neurology, 2003
- Recommendations for using opioids in chronic non‐cancer painEuropean journal of pain, 2003